Featured Editorial

1. Nanosystems And Rare Diseases: Opportunities And Limitations 3/27/2026

   Nanosystems offer unique capabilities, enabling researchers to design precise, versatile delivery systems that address key challenges in rare diseases.

2. 3 Emerging Trends In Drug Delivery Device Pipelines 3/18/2026

   When analyzing the drug delivery product pipeline, three key technologies stand out. Check out the latest market research.

3. Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables 3/17/2026

   A new draft guidance document from ICH, issued jointly with the EMA, adopts the position that the assessment of leachables and extractables requires a holistic framework for risk evaluation.

4. Closing The Adherence Gap: The Connected Health Era 3/13/2026

   Connected health is shifting healthcare from reactive to proactive by enabling providers to oversee drug delivery while allowing patients to actively engage in their care.

5. Delivery Strategy For Next-Gen Cardiac Gene Therapies 3/12/2026

   As the field matures, the most transformative gene therapies in heart health are treating delivery not as an afterthought but as a fundamental principle.

6. The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To Nephrology 3/6/2026

   Nanomedicines are solving the drug delivery problem in kidney disease. The next step: bridging the translational gap to advance these technologies into the clinic.

7. Injecting Cancer Killers: Intratumoral Therapy For Solid Tumors 3/5/2026

   Intratumoral injection bypasses the tumor’s physical defenses entirely, killing cancer cells and creating a personalized immune response that destroys solid tumors.

8. The Advantages Of Antibodies Over Ligands In The Alpha Emitter Era 3/5/2026

   The alpha era in radiopharmaceuticals is still being defined. The choices developers make now about delivery platforms will shape individual programs and the trajectory of the field.

9. GenAI: The Muscle Behind Strong Regulatory Intelligence For Combination Products 3/2/2026

   In this article, combination product consultant Doug Mead provides the rationale and offers guidance for using GenAI tools to search regulatory databases. He shows the benefits for biopharma developers of conducting “precedent research” into previous regulatory pathways and results for similar or related drug delivery product submissions. 

10. Regulatory Precedents For Drug Delivery: Uncovering Clues To Successful Submissions 3/2/2026

    In this article, Chief Editor Tom von Gunden considers the need for and benefit of conducting AI-based research into regulatory precedents for drug delivery submissions and approvals. He consults combination products consultant Doug Mead on best practices in bolstering regulatory intelligence and regulatory approval success by way of advanced search methods.